EUVIMEDEUVIMED entdecken
KorrekturOpen Access · CC BY 4.0

Correction to “Development of an Agent‐Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec”

CPT: Pharmacometrics & Systems Pharmacology · 2026-08 · 15 (8)

DOI: 10.1002/psp4.70312 ↗

Kurz gefasst

Korrektur in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 27.07.2026. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Li, Y, Nandy, P, Jordie, E, et al., “ Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec.” CPT: Pharmacometrics and Systems Pharmacology 2026; 15(7):e70286. https://doi.org/10.1002/psp4.70286. In the first paragraph of the “3.2 Long-Term Predictions and Drivers of Durability” section, the text “The model-predicted mean FIX activity at Year 5 was 23.5% (95% CI 4.92%, 72.2%), overlapping with the reported range of 31.6% ± 15.7% (mean ± standard deviation) [31].” was incorrect. This should have read: “The model-predicted mean FIX activity at Year 5 was 27.7% (95% CI 4.92%, 72.2%), overlapping with the reported range of 31.6% ± 15.7% (mean ± standard deviation) [31].” We apologize for this error.

Zitieren

APA

(2026). Correction to “Development of an Agent‐Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec”. CPT: Pharmacometrics & Systems Pharmacology, 15(8). https://doi.org/10.1002/psp4.70312

Vancouver

Correction to “Development of an Agent‐Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec”. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(8). doi:10.1002/psp4.70312

BibTeX
@article{euvimed2026,
  title = {Correction to “Development of an Agent‐Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec”},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {8},
  doi = {10.1002/psp4.70312}
}
Kostenlos starten →